Collects royalties from a pharmaceutical partner on respiratory medicines and sells critical-care and infectious-disease medicines for hospital care, alongside strategic healthcare investments.
10-K for FY2025, filed Feb 25, 2026Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company…View ↗
Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone…View ↗
Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated…View ↗
In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development…View ↗
GSK pays royalties on partnered respiratory medicines. Hospitals, health systems and government facilities are end users of Innoviva’s medicines, with distributors involved in some sales.
10-K for FY2025, filed Feb 25, 2026Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (“GSK”), including RELVAR®/BREO® ELLIPTA® (fluticasone…View ↗
Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated…View ↗
Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the…View ↗
Yes. It kept 66 cents of every revenue dollar as net income in FY2025 and turned 48 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$73.9MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
“Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and continued excellent…View ↗
Broader commercial portfolio
The hospital and infectious-disease business has broadened from GIAPREZA and XERAVA as marketed products, with SUL-DUR in development, to a wider commercial portfolio that includes XACDURO, ZEVTERA and NUZOLVENCE.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 25, 2026We expanded our portfolio of royalties and innovative healthcare assets through the acquisition of Entasis Therapeutics Holdings Inc.…View ↗
Our critical care and infectious disease portfolio was formed through the 2022 acquisitions of Entasis Therapeutics and La Jolla…View ↗
XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and…View ↗
ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, including…View ↗
NUZOLVENCE® (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital…View ↗
Competes with GSK, AstraZeneca, TEVA, Boehringer Ingelheim, Merck, Novartis, Sunovion, Chiesi, Genentech, Sanofi Genzyme, and Amgen
10-K for FY2025, filed Feb 25, 2026Advair®/Seretide™ Diskus®/HFA® (salmeterol and fluticasone propionate as a combination) marketed by GSKView ↗
Loading...